Investors have recently focused on the NCE status for Amarin's (NASDAQ: AMRN) triglyceride-lowering drug Vascepa and potential suitors for the company, but many might be overlooking a topic that is essential to the future of this biotech stock: patents.

A cascade of patents protecting Vascepa from generic competitors has been rolling in lately, and Amarin is keen on obtaining more IP for its flagship product. In this video, health-care analysts Max Macaluso and Brenton Flynn talk about the drug's latest patents, and discuss why they are so vital for Amarin today.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.